Aamna AlShehhi

Aamna AlShehhi

Auto-generated profile, based on publicly available information

Aamna AlShehhi

Department of Electrical Engineering Khalifa University Abu Dhabi United Arab Emirates

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SJSherlyn Jemimah
Sherlyn Jemimah
CCChahd Maher Musthafa Chabib
Chahd Maher Musthafa Chabib
LHLeontios Hadjileontiadis
Leontios Hadjileontiadis
AAAamna AlShehhi
Aamna AlShehhi
Background: Alzheimer’s disease (AD) is a neurodegenerative disorder that causes gradual memory loss. AD and its prodromal stage of mild cognitive impairment (MCI) are marked by significant gut microbiome perturbations, also known as gut dysbiosis. However, the direction and extent of gut dysbiosis have not been elucidated. Therefore, we performed a meta-analysis and systematic review of 16S gut microbiome studies to gain insights into gut dysbiosis in AD and MCI. Methods: We searched MEDLINE, Scopus, EMBASE, EBSCO, and Cochrane for AD gut microbiome studies published between Jan 1, 2010 and Mar 31, 2022. This study has two outcomes: primary and secondary. The primary outcomes explored the changes in α-diversity and relative abundance of microbial taxa, which were analyzed using a variance-weighted random-effects model. The secondary outcomes focused on qualitatively summarized β-diversity ordination and linear discriminant analysis effect sizes. The risk of bias was assessed using a methodology appropriate for the included case-control studies. The geographic cohorts’ heterogeneity was examined using subgroup meta-analyses if sufficient studies reported the outcome. The study protocol has been registered with PROSPERO (CRD42022328141). Findings: Seventeen studies with 679 AD and MCI patients and 632 controls were identified and analyzed. The cohort is 61.9% female with a mean age of 71.3±6.9 years. The meta-analysis shows an overall decrease in species richness in the AD gut microbiome. However, the phylum Bacteroides is consistently higher in US cohorts (standardised mean difference [SMD] 0.75, 95% confidence interval [CI] 0.37 to 1.13, p < 0.01) and lower in Chinese cohorts (SMD -0.79, 95% CI -1.32 to -0.25, p < 0.01). Moreover, the Phascolarctobacterium genus is shown to increase significantly, but only during the MCI stage. Discussion: Notwithstanding possible confounding from polypharmacy, our findings show the relevance of diet and lifestyle in AD pathophysiology. Our study presents evidence for region-specific changes in abundance of Bacteroides, a major constituent of the microbiome. Moreover, the increase in Phascolarctobacterium and the decrease in Bacteroides in MCI subjects shows that gut microbiome dysbiosis is initiated in the prodromal stage. Therefore, studies of the gut microbiome can facilitate early diagnosis and intervention in Alzheimer’s disease and perhaps other neurodegenerative disorders.

2 May 2023 in IEEE Access
Verified
Journal Article
Open access
CCChahd M. Chabib
Chahd M. Chabib
LHLeontios J. Hadjileontiadis
Leontios J. Hadjileontiadis
ASAamna Al Shehhi
Aamna Al Shehhi
Alzheimer’s Disease (AD) is the most common form of dementia. It usually manifests through progressive loss of cognitive function and memory, subsequently impairing the person’s ability to live without assistance and causing a tremendous impact on the affected individuals and society. Currently, AD diagnosis relies on cognitive tests, blood tests, behavior assessments, brain imaging, and medical history analysis. However, these procedures are subjective and inconsistent, making an accurate prediction for the early stages of AD difficult. This paper introduces a curvelet transform (CT) based-convolutional neural network (CNN) (DeepCurvMRI) model for improving the accuracy of early-stage AD disease detection using from Magnetic resonance imaging (MRI) images. The MRI images were first pre-processed using CT, and then a CNN model was trained using the new image representation. In this study, we used Alzheimer’s MRI images dataset hosted on the Kaggle platform to train DeepCurvMRI for multi and binary classification tasks. DeepCurvMRI achieved an accuracy, sensitivity, specificity, and F1 score of 98.62% ± 0.10%, 99.05%±0.10%, 98.50%±0.03%, and 99.21±0.08, respectively, using the leave-one-group-out (LOGO) cross-validation approach in multi-classification task. The highest accuracy obtained in binary classification is 98.71% ± 0.05%. In addition to LOGO, DeepCurvMRI was tested using randomly stratified 10-fold and 5-fold cross validation. These encouraging results are superior to the ones reported in related methods, showcasing the potentiality of DeepCurvMRI in capturing the key anatomical changes in MRI images that can be differentiated between various staged of Alzheimer’s disease classes.

13 March 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MAMuaath Ebrahim AlMansoori
Muaath Ebrahim AlMansoori
SJSherlyn Jemimah
Sherlyn Jemimah
FAFerial Abuhantash
Ferial Abuhantash
AAAamna AlShehhi
Aamna AlShehhi
Alzheimer’s disease (AD) is an incurable neurodegenerative disorder that leads to dementia. This study employs explainable machine learning models to detect dementia cases using blood gene expression, single nucleotide polymorphisms (SNPs), and clinical data from Alzheimer’s Disease Neuroimaging Initiative (ADNI). Analyzing 623 ADNI participants, we found that the Support Vector Machine classifier with Mutual Information (MI) feature selection, trained on all three data modalities, achieved exceptional performance (accuracy = 0.95, AUC = 0.94). When using gene expression and SNP data separately, we achieved very good performance (AUC = 0.65, AUC = 0.63, respectively). Using SHapley Additive exPlanations (SHAP), we identified significant features, potentially serving as AD biomarkers. Notably, genetic-based biomarkers linked to axon myelination and synaptic vesicle membrane formation could aid early AD detection. In summary, this genetic-based biomarker approach, integrating machine learning and SHAP, shows promise for precise AD diagnosis, biomarker discovery, and offers novel insights for understanding and treating the disease. This approach addresses the challenges of accurate AD diagnosis, which is crucial given the complexities associated with the disease and the need for non-invasive diagnostic methods.

17 October 2023 in IEEE Transactions on Neural Systems and Rehabilitation Engineering
Verified
Journal Article
Open access
RKRateb Katmah
Rateb Katmah
ASAamna Al Shehhi
Aamna Al Shehhi
HJHerbert Jelinek
Herbert Jelinek
AHAbdul Aziz Hulleck
Abdul Aziz Hulleck
KKKinda Khalaf
Kinda Khalaf
Background: Neurological diseases are a leading cause of disability and mortality. Gait, or human walking, is a significant predictor of quality of life, morbidity, and mortality. Gait patterns and other kinematic, kinetic, and balance gait features are accurate and powerful diagnostic and prognostic tools. Objective: This review article focuses on the applicability of gait analysis using fusion techniques and artificial intelligence (AI) models. The aim is to examine the significance of mixing several types of wearable and non-wearable sensor data and the impact of this combination on the performance of AI models. Method: In this systematic review, 66 studies using more than two modalities to record and analyze gait were identified. 40 studies incorporated multiple gait analysis modalities without the use of artificial intelligence to extract gait features such as kinematic, kinetic, margin of stability, temporal, and spatial gait parameters, as well as cerebral activity. Similarly, 26 studies analyzed gait data using multimodal fusion sensors and AI algorithms. Results: The research summarized here demonstrates that the quality of gait analysis and the effectiveness of AI models can both benefit from the integration of data from many sensors. Meanwhile, the utilization of EMG signals in fusion data is especially advantageous. Conclusion: The findings of this review suggest that a smart, portable, wearable-based gait and balance assessment system can be developed using multimodal sensing of the most cutting-edge, clinically relevant tools and technology available. The information presented in this article may serve as a vital springboard for such development.

10 September 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FAFerial Abuhantash
Ferial Abuhantash
MHMohd Khalil Abu Hantash
Mohd Khalil Abu Hantash
AAAamna AlShehhi
Aamna AlShehhi
Alzheimer’s disease (AD), the most prevalent form of dementia, requires early prediction for timely intervention. Current deep learning approaches, particularly those using traditional neural networks, face challenges such as handling high-dimensional data, interpreting complex relationships, and managing data bias. To address these limitations, we propose a framework utilizing graph neural networks (GNNs), which excel in modeling relationships within graph-structured data. Our study employs GNNs on data from the Alzheimer’s Disease Neuroimaging Initiative for binary and multi-class classification across the three stages of AD: cognitively normal (CN), mild cognitive impairment (MCI), and Alzheimer’s disease (AD). By incorporating comorbidity data derived from electronic health records, we achieved the most effective multi-classification results. Notably, the GNN model (Chebyshev Convolutional Neural Networks) demonstrated superior performance with a 0.98 accuracy in multi-class classification and 0.99, 0.93, and 0.94 in the AD/CN, AD/MCI, and CN/MCI binary tasks, respectively. The model’s robustness was further validated using the Australian Imaging, Biomarker & Lifestyle dataset as an external validation set. This work contributes to the field by offering a robust, accurate, and cost-effective method for early AD prediction (CN vs. MCI), addressing key challenges in existing deep learning approaches.

3 October 2024 in IEEE Access
Verified
Journal Article
Open access
CLCharalampos Lamprou
Charalampos Lamprou
KKKyriaki Katsikari
Kyriaki Katsikari
NRNoora Rahmani
Noora Rahmani
LHLeontios Hadjileontiadis
Leontios Hadjileontiadis
MSMohamed Seghier
Mohamed Seghier
AAAamna Alshehhi
Aamna Alshehhi
Despite the emergence of numerous Deep Learning (DL) models for breast cancer detection via mammograms, there is a lack of evidence about their robustness to perform well on new unseen mammograms. To fill this gap, we introduce StethoNet, a DL-based framework that consists of multiple Convolutional Neural Network (CNN) trained models for classifying benign and malignant tumors. StethoNet was trained on the Chinese Mammography Database (CMMD), and tested on unseen images from CMMD, as well as on images from two independent datasets, i.e., the Vindr-Mammo and the INbreast datasets. To mitigate domain-shift effects, we applied an effective entropy-based domain adaptation technique at the preprocessing stage. Furthermore, a Bayesian hyperparameters optimization scheme was implemented for StethoNet optimization. To ensure interpretable results that corroborate with prior clinical knowledge, attention maps generated using Gradient-weighted Class Activation Mapping (GRAD-CAM) were compared with Regions of Interest (ROIs) identified by radiologists. StethoNet achieved impressive Area Under the receiver operating characteristics Curve (AUC) scores: 90.7% (88.6%-92.8%), 83.9% (76.0%-91.8%), and 85.7% (82.1%-89.4%) for the CMMD, INbreast, and Vindr-Mammo datasets, respectively. These results surpass the current state of the art and highlight the robustness and generalizability of StethoNet, scaffolding the integration of DL models into breast cancer mammography screening workflows.